Zoetis Inc. Investors Can Pursue Class Action Lawsuit for Losses

Zoetis Inc. Class Action Lawsuit Opportunity

SAN DIEGO, June 18, 2026 — Robbins Geller Rudman & Dowd LLP has announced a significant opportunity for investors in Zoetis Inc. (NYSE: ZTS) who incurred substantial financial losses between January 14, 2025, and May 6, 2026. The firm is seeking individuals interested in leading a class action lawsuit against the company, which has been accused of misleading investors regarding its financial performance and product safety.

The lawsuit, titled City of Ann Arbor Retiree Health Care Benefit Plan Trust v. Zoetis Inc., is currently filed in the Southern District of New York as case number 26-cv-04401. It alleges violations of the Securities Exchange Act of 1934 by the company and key executives.

Allegations Against Zoetis

The claims in this class action revolve around the assertion that Zoetis engaged in deceptive practices that affected its stock value adversely. Allegedly, throughout the class period, the company made false statements and did not disclose critical information about the market performance of its prominent products, particularly in the companion animal health sector.

1. Decreased Prescription Growth: One major point of concern is the decline in veterinarian prescription growth for Librela, a pain management drug for dogs. Following FDA warnings regarding serious neurological issues, vets became increasingly hesitant to prescribe this medication.

2. Loss of Market Share: Zoetis’ product Simparica Trio was reportedly losing market share to a more affordable competitor that offers broader applications in a contracting market. Furthermore, both Apoquel and Cytopoint, which are dermatology products, faced aggressive competition from newly launched canine treatments.

Financial Impact on Investors

The situation escalated with the release of Zoetis’ second quarter financial results on August 5, 2025, when reports indicated a downturn in demand for their companion animal products. Following this news, the company's stock price dropped by nearly 4%. The decline in stock value continued, with a staggering drop of around 14% after the third quarter results were released on November 4, 2025.

The fourth quarter results on February 12, 2026, further reiterated the declining trajectory, prompting another fall in stock prices. By May 7, 2026, when the first quarter financial results for 2026 were disclosed, the stock plummeted by more than 21%, reflecting the mounting pressures on the company’s competitive position in the market.

Calling Potential Lead Plaintiffs

Investors who bought Zoetis securities during the class period have until Monday, July 27, 2026, to seek the position of lead plaintiff in this lawsuit. Lead plaintiffs typically possess the most significant financial stake in the case, and they play a pivotal role in guiding the litigation. As lead plaintiff, you may select your own legal representation from the law firms suited to handle such securities cases. Importantly, participation as lead plaintiff does not affect the potential for future recovery from the case.

Robbins Geller Rudman & Dowd LLP asserts its expertise in representing investors against securities fraud. The firm has a strong track record, having recovered over $916 million for investors in 2025 alone and achieving several top rankings in securities litigation.

Conclusion

For those affected by the financial missteps of Zoetis Inc., this class action lawsuit presents a critical opportunity to seek justice and potential recovery of losses. Interested parties are encouraged to visit Robbins Geller’s website or contact attorneys Ken Dolitsky or Michael Albert at 800/851-7783 for more information.